Drug intelligence / Profile preview

whole cell euglena gracilis

Development stage
Unknown
Lead developer
Solabia-Algatech Nutrition
Modality
Small Molecules
Administration
Oral
01

Overview

Whole cell euglena gracilis, marketed as BioGlena™, is a natural dietary supplement ingredient developed by Solabia-Algatech Nutrition. It consists of the whole dried microalgae, *Euglena gracilis*, which is produced via a proprietary fermentation process. [5, 10] The product's primary active component is paramylon, a linear β-1,3-glucan, which constitutes a minimum of 50-55% of its content, along with complete proteins, vitamins, and minerals. [1, 2] BioGlena™ is designed for immune support and acts as an immunomodulator. [1, 5] It functions by targeting the Dectin-1 receptor on innate immune cells, like macrophages, to induce a state of 'trained immunity'. [1, 4, 10] This process involves a functional reprogramming of the immune cells, leading to a stronger and faster response to subsequent pathogenic challenges. [1, 5] The product is administered orally and is available as a powder for use in capsules, tablets, gummies, and functional foods. [1] It has been approved as a novel food by the EFSA and is recognized as GRAS (Generally Recognized as Safe) by the FDA. [1, 10]

Brand names
BioGlena
Other names
whole cell euglena containing beta glucanEuglena gracilis whole algae powder
02

Targets

αMβ2 (Integrin αMβ2)CLEC7A (Dectin-1)

Beyond the preview

Go deeper on whole cell euglena gracilis.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on whole cell euglena gracilis.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call